EN
icon
CN
CN | EN
We have a robust and sustainable pipeline with 4 clinical stage assets (EMB-01, EMB-02 , EMB-06 and EMB-09) and more than 10 preclinical stage candidates. Our proprietary FIT-Ig® platform and other technical capabilities enable us to target three strategic oncology areas (tumor targeting, dual checkpoint regulators, immune cell engagers) and maintain our strong momentum to advance additional preclinical assets to the clinic.
Pipeline
PipeLine
Targerts & Indications
Global Rights
Preclinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ
EMB-01
EGFR/cMET in NSCLC, Monotherapy
Global Rights
EMB-01 is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to simultaneously target EGFR and cMet on tumor cells. It is being studied in Phase I/II clinical trials in NSCLC as well as several GI indications in the U.S. and China.
EMB-01
EGFR/cMET in NSCLC, Combo with Tagrisso®
Global Rights
EMB-01 is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to simultaneously target EGFR and cMet on tumor cells. It is being studied in Phase I/II clinical trials in NSCLC as well as several GI indications in the U.S. and China.
EMB-01
EGFR/cMET in GI Cancers, Monotherapy
Global Rights
EMB-01 is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to simultaneously target EGFR and cMet on tumor cells. It is being studied in Phase I/II clinical trials in NSCLC as well as several GI indications in the U.S. and China.
EMB-02
PD-1/LAG-3 in Solid Tumor
Global Rights
EMB-02 is a bispecific antibody targeting human programmed cell death protein 1 (PD-1) and lymphocyte-activation gene 3 (LAG-3) and is being evaluated in advanced solid tumors. This antibody is designed to target human PD-1 and LAG-3 concomitantly or independently and disrupt the immune suppression mediated by both pathways, thereby restoring T-cell effector function and enhancing anti-cancer activity. Currently, a global Phase I/II study is ongoing with sites opened in US, Australia, and China.
EMB-06
BCMA/CD3 in Multiple Myeloma
Global Rights
EMB-06 is a recombinant humanized bispecific antibody targeted against B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3). Upon binding to BCMA on tumor cell surface, EMB-06 can recruit and activate CD3 expressing T lymphocytes, thereby mediating the killing effect of T lymphocytes on tumor cells. Currently, a global Phase I/II study is enrolling patients in Australia and China.
EMB-09
PD-L1/OX40 in Solid Tumor
Global Rights
EMB-09 is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to block PD-1/PD-L1 inhibitory signaling, and conditionally activate T effector cells by stimulating OX40 through PD-L1 dependent cross linking. EMB-09 showed superior immune cell activation in comparison with the mAb combinations. Its unique OX40 binding epitope could improve the therapeutic window, and silenced Fc effector function can avoid T effector cell depletion.
EMB-07
TAA/CD3 in Solid Tumor & Hematologic Malignancies
Global Rights
EMB-07 is a T cell redirecting bispecific antibody by targeting a novel tumor associated antigen (TAA) and cluster of differentiation 3 (CD3). EMB-07 is designed based on EpimAb’s proprietary bispecific antibody platform. Upon binding to TAA on the tumor cell surface, EMB-07 can recruit and activate CD3 expressing T lymphocytes, thereby promoting the cytotoxic effect of T lymphocytes. EMB-07 showed a promising preclinical efficacy and safety profile. IND submission is expected in 2022.